Literature DB >> 25645730

Increased chronic lymphocytic leukemia proliferation upon IgM stimulation is sustained by the upregulation of miR-132 and miR-212.

Simona Tavolaro1, Teresa Colombo, Sabina Chiaretti, Nadia Peragine, Valerio Fulci, Maria R Ricciardi, Monica Messina, Silvia Bonina, Fulvia Brugnoletti, Marilisa Marinelli, Valeria Di Maio, Francesca R Mauro, Ilaria Del Giudice, Giuseppe Macino, Robin Foà, Anna Guarini.   

Abstract

To assess the involvement of microRNAs (miRNAs) in B-cell receptor (BCR) stimulation, we first evaluated miRNA profiling following IgM cross-linking in chronic lymphocytic leukemia (CLL) cells and in normal B lymphocytes. Second, we combined miRNA and gene expression data to identify putative miRNA functional networks. miRNA profiling showed distinctive patterns of regulation after stimulation in leukemic versus normal B lymphocytes and identified a differential responsiveness to BCR engagement in CLL subgroups according to the immunoglobulin heavy chain variable region mutational status and clinical outcome. The most significantly modulated miRNAs in stimulated CLL are miR-132 and miR-212. Notably, these miRNAs appeared regulated in progressive but not in stable CLL. Accordingly, gene profiling showed a significant transcriptional response to stimulation exclusively in progressive CLL. Based on these findings, we combined miRNA and gene expression data to investigate miR-132 and miR-212 candidate interactions in this CLL subgroup. Correlation analysis pointed to a link between these miRNAs and RB/E2F and TP53 cascades with proproliferative effects, as corroborated by functional analyses. Finally, basal levels of miR-132 and miR-212 were measured in an independent cohort of 20 unstimulated CLL cases and both showed lower expression in progressive compared to stable patients, suggesting an association between the expression of these molecules and disease prognosis. Overall, our results support a model involving miR-132 and miR-212 upregulation in sustaining disease progression in CLL. These miRNAs may therefore provide new valuable strategies for therapeutic intervention.
© 2015 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25645730     DOI: 10.1002/gcc.22236

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  18 in total

1.  Duvelisib treatment is associated with altered expression of apoptotic regulators that helps in sensitization of chronic lymphocytic leukemia cells to venetoclax (ABT-199).

Authors:  V M Patel; K Balakrishnan; M Douglas; T Tibbitts; E Y Xu; J L Kutok; M Ayers; A Sarkar; R Guerrieri; W G Wierda; S O'Brien; N Jain; H M Stern; V Gandhi
Journal:  Leukemia       Date:  2016-12-26       Impact factor: 11.528

Review 2.  miRNAs in B Cell Development and Lymphomagenesis.

Authors:  Maryaline Coffre; Sergei B Koralov
Journal:  Trends Mol Med       Date:  2017-07-07       Impact factor: 11.951

Review 3.  Evasion and interactions of the humoral innate immune response in pathogen invasion, autoimmune disease, and cancer.

Authors:  Trisha A Rettig; Julie N Harbin; Adelaide Harrington; Leonie Dohmen; Sherry D Fleming
Journal:  Clin Immunol       Date:  2015-07-02       Impact factor: 3.969

4.  MicroRNA-212 functions as an epigenetic-silenced tumor suppressor involving in tumor metastasis and invasion of gastric cancer through down-regulating PXN expression.

Authors:  Daojiang Li; Zhengrong Li; Jianbo Xiong; Binbin Gong; Guoyang Zhang; Chao Cao; Zhigang Jie; Yi Liu; Yi Cao; Yufeng Yan; Hong Xiong; Lingyu Qiu; Miantian Yang; Hongping Chen; Shuping Jiang; Xiongwen Yang; Heping Chen
Journal:  Am J Cancer Res       Date:  2015-09-15       Impact factor: 6.166

5.  MicroRNA-212 targets FOXA1 and suppresses the proliferation and invasion of intrahepatic cholangiocarcinoma cells.

Authors:  Lei Zhu; Feizhou Huang; Gang Deng; Wanpin Nie; Wei Huang; Hongbo Xu; Shaopeng Zheng; Zhongjie Yi; Tao Wan
Journal:  Exp Ther Med       Date:  2016-10-19       Impact factor: 2.447

6.  Residual expression of SMYD2 and SMYD3 is associated with the acquisition of complex karyotype in chronic lymphocytic leukemia.

Authors:  Wilson Oliveira-Santos; Doralina Amaral Rabello; Antônio Roberto Lucena-Araujo; Fábio Morato de Oliveira; Eduardo Magalhaes Rego; Fábio Pittella Silva; Felipe Saldanha-Araujo
Journal:  Tumour Biol       Date:  2016-01-20

7.  The microRNA-212/132 cluster regulates B cell development by targeting Sox4.

Authors:  Arnav Mehta; Mati Mann; Jimmy L Zhao; Georgi K Marinov; Devdoot Majumdar; Yvette Garcia-Flores; Xiaomi Du; Erdem Erikci; Kamal Chowdhury; David Baltimore
Journal:  J Exp Med       Date:  2015-09-14       Impact factor: 14.307

8.  The SIRT1/TP53 axis is activated upon B-cell receptor triggering via miR-132 up-regulation in chronic lymphocytic leukemia cells.

Authors:  Michele Dal Bo; Tiziana D'Agaro; Stefania Gobessi; Antonella Zucchetto; Sara Dereani; Davide Rossi; Francesco Zaja; Gabriele Pozzato; Francesco Di Raimondo; Gianluca Gaidano; Luca Laurenti; Giovanni Del Poeta; Dimitar G Efremov; Valter Gattei; Riccardo Bomben
Journal:  Oncotarget       Date:  2015-08-07

Review 9.  Clinical significance of microRNAs in chronic and acute human leukemia.

Authors:  Chien-Hung Yeh; Ramona Moles; Christophe Nicot
Journal:  Mol Cancer       Date:  2016-05-14       Impact factor: 27.401

10.  Cholinergic Machinery as Relevant Target in Acute Lymphoblastic T Leukemia.

Authors:  Oxana Dobrovinskaya; Georgina Valencia-Cruz; Luis Castro-Sánchez; Edgar O Bonales-Alatorre; Liliana Liñan-Rico; Igor Pottosin
Journal:  Front Pharmacol       Date:  2016-08-31       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.